BMY — Bristol-Myers Squibb Co Balance Sheet
0.000.00%
Last trade - 00:00
- $97.85bn
- $125.40bn
- $45.01bn
- 91
- 73
- 51
- 83
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15,393 | 15,831 | 17,221 | 9,253 | 12,280 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 7,685 | 8,501 | 12,516 | 13,937 | 15,264 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 29,354 | 30,192 | 33,262 | 27,273 | 31,770 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 6,956 | 6,745 | 6,968 | 7,475 | 8,036 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 129,944 | 118,481 | 109,314 | 96,820 | 95,159 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18,304 | 19,080 | 21,868 | 21,890 | 22,262 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 78,346 | 80,659 | 73,368 | 65,759 | 65,729 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 51,598 | 37,822 | 35,946 | 31,061 | 29,430 |
Total Liabilities & Shareholders' Equity | 129,944 | 118,481 | 109,314 | 96,820 | 95,159 |
Total Common Shares Outstanding |